Previous 10 | Next 10 |
In March, the coronavirus pandemic forced Codexis (NASDAQ: CDXS) to temporarily close its research facilities. Although the company began reopening in May and expects to be close to full operating capacity by the end of the summer, the coronavirus pandemic had a negative impact on the busine...
Codexis, Inc. (CDXS) Q2 2020 Earnings Conference Call August 06, 2020, 16:30 ET Company Participants Bruce Voss - Lippert/Heilshorn & Associates John Nicols - President, CEO & Director Ross Taylor - SVP & CFO Conference Call Participants Matthew Hewitt - Craig-H...
Codexis (NASDAQ: CDXS ) : Q2 Non-GAAP EPS of -$0.07 beats by $0.06 ; GAAP EPS of -$0.11 beats by $0.08 . More news on: Codexis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Revenues increased 21% to $15 million; 72% rise in R&D revenue included a significant contribution from the Takeda biotherapeutics partnership Conference call with slides begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Codexis, In...
REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announced the appointment of Jennifer L. Aaker, Ph.D. to its board of directors, expanding membership to nine directors. Dr....
REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020. Codexis management will hold an investment communi...
Codexis (NASDAQ: CDXS ) and Molecular Assemblies, Inc., announce a partnership to engineer enzymes to deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA. More news on: Codexis, Inc., Healthcare stocks news, Read more ...
REDWOOD CITY, Calif. and SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announce a partnership to e...
REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D. at the companyȁ...
REDWOOD CITY, Calif. and JUPITER, Fla., June 01, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metabolizing enzy...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...